Formatech, Inc. to Donate Services to Manufacture KAI Pharmaceuticals, Inc.'s Clinical Candidate Under Its "Fillanthropy(TM) Program"
11/18/2009 9:35:04 AM
More...
|
KAI Pharmaceuticals, Inc. Reports Positive Preclinical Results in Pain Therapeutic Program Targeting Gamma Protein Kinase C (PKC) Pathway
10/20/2009 9:35:19 AM
More...
|
KAI Pharmaceuticals, Inc. Acquires Patents from Progen Pharmaceuticals Limited (PGLA), Broadening KAI's Intellectual Property Estate Covering Peptide-Based Therapies
6/30/2009 11:02:43 AM
More...
|
KAI Pharmaceuticals, Inc. Initiates Third Phase 2a Study in Program to Develop KAI-1678 for the Treatment of Neuropathic Pain
4/8/2009 9:40:18 AM
More...
|
KAI Pharmaceuticals, Inc. Expands KAI-1678 Development Program, Initiating a Phase 2a Study for Neuropathic Pain
3/31/2009 10:02:43 AM
More...
|
KAI Pharmaceuticals, Inc. Initiates Phase 2b Clinical Study of KAI-9803 in Heart Attack Patients
12/17/2008 9:05:38 AM
More...
|
KAI Pharmaceuticals, Inc. Release: KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing for the Treatment of Pain
12/10/2008 10:15:02 AM
More...
|
KAI Pharmaceuticals, Inc. Reports Positive Preclinical Results for KAI-1678, First-in-Class Compound to Treat Pain
11/19/2008 9:10:17 AM
More...
|
KAI Pharmaceuticals, Inc. Advances Third Product Candidate into Clinical Studies
5/20/2008 8:53:15 AM
More...
|
KAI Pharmaceuticals, Inc. Initiates Phase 1 Trial of KAI-1455 for Ischemic Injury
5/4/2007 1:11:24 PM
More...
|
|